Corcept Therapeutics (CORT) Revenue: 2009-2025
Historic Revenue for Corcept Therapeutics (CORT) over the last 13 years, with Sep 2025 value amounting to $207.6 million.
- Corcept Therapeutics' Revenue rose 13.75% to $207.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $741.2 million, marking a year-over-year increase of 17.92%. This contributed to the annual value of $675.0 million for FY2024, which is 39.94% up from last year.
- Per Corcept Therapeutics' latest filing, its Revenue stood at $207.6 million for Q3 2025, which was up 6.79% from $194.4 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' Revenue registered a high of $207.6 million during Q3 2025, and its lowest value of $79.4 million during Q1 2021.
- Its 3-year average for Revenue is $156.1 million, with a median of $157.2 million in 2025.
- As far as peak fluctuations go, Corcept Therapeutics' Revenue declined by 14.81% in 2021, and later soared by 47.69% in 2024.
- Quarterly analysis of 5 years shows Corcept Therapeutics' Revenue stood at $98.8 million in 2021, then rose by 4.28% to $103.1 million in 2022, then skyrocketed by 31.39% to $135.4 million in 2023, then surged by 34.33% to $181.9 million in 2024, then climbed by 13.75% to $207.6 million in 2025.
- Its last three reported values are $207.6 million in Q3 2025, $194.4 million for Q2 2025, and $157.2 million during Q1 2025.